Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Zacks Small Cap Research on MSN3d
HURA: Initiating an Immune ResponseHURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...
H.C. Wainwright maintained a Buy rating on Kura Oncology (NASDAQ:KURA) and raised the price target to $40.00 from the previous $37.00. Trading at $9.05, the stock has seen a strong 12.7% gain over the ...
Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...
Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...
We focus AML with mutations of the Nucleophosmin gene (NPM1) and show evidence to suggest that wild-type NPM1 has an inhibitory influence on BRD4 that is relieved upon NPM1c mutation and ...
Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...
Kura Oncology与Kyowa Kirin日前宣布，在研疗法ziftomenib，在治疗复发/难治性（R/R）NPM1突变（NPM1-m）急性髓系白血病（AML）患者的注册性2期临床试验KOMET-001中取得积极的顶线结果。Ziftomenib是一种高选择性、每日一次口服的在研menin抑制剂。KOMET-001的顶线数据计划于2025年第二季度的医学会议上展示。同时，Kura正按计划于 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback